Comparing Adoption of Breakthrough and “Me-too” Drugs Among Medicare Beneficiaries: a Case Study of Dipeptidyl Peptidase-4 Inhibitors

被引：0
|
作者：
Inmaculada Hernandez
Yuting Zhang
机构：
[1] University of Pittsburgh,Department of Pharmacy and Therapeutics
[2] University of Pittsburgh,Department of Health Policy and Management
来源：
Journal of Pharmaceutical Innovation | 2017年 / 12卷
关键词：
Diffusion of innovation; Prescription drugs; Medicare Part D; Medicare Advantage;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：105 / 109
页数：4
相关论文
共 50 条
  • [31] Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015
    Crowley, Matthew J.
    Gokhale, Mugdha
    Pate, Virginia
    Stuermer, Til
    Buse, John B.
    DIABETES OBESITY & METABOLISM, 2019, 21 (04): : 854 - 865
  • [32] Association between therapy with dipeptidyl peptidase-4 (DPP-4) inhibitors and risk of ileus: a cohort study
    Bennett D.
    Davé S.
    Sakaguchi M.
    Chang C.-H.
    Dolin P.
    Diabetology International, 2016, 7 (4) : 375 - 383
  • [33] Cardiovascular risks associated with dipeptidyl peptidase-4 inhibitors monotherapy compared with other antidiabetes drugs in the Japanese population: A nationwide cohort study
    Komamine, Maki
    Kajiyama, Kazuhiro
    Ishiguro, Chieko
    Uyama, Yoshiaki
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 (09) : 1166 - 1174
  • [34] Cardiovascular safety signals with dipeptidyl peptidase-4 inhibitors: A disproportionality analysis among high-risk patients
    Baksh, Sheriza N.
    McAdams-DeMarco, Mara
    Segal, Jodi B.
    Alexander, G. Caleb
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 (06) : 660 - 667
  • [35] Temporal Changes in Inpatient and Outpatient Hypoglycemia among Patients Treated with Sulfonylureas or Dipeptidyl Peptidase-4 Inhibitors in the US
    Tang, Yuexin
    Liu, Jinan
    Rajpathak, Swapnil
    Engel, Samuel S.
    Hannachi, Hakima
    DIABETES, 2017, 66 : A586 - A586
  • [36] Cardiovascular Outcomes of Dipeptidyl Peptidase-4 Inhibitors in Elderly Patients With Type 2 Diabetes: A Nationwide Study
    Shih, Chia-Jen
    Chen, Hung-Ta
    Kuo, Shu-Chen
    Ou, Shuo-Ming
    Chen, Yung-Tai
    JOURNAL OF THE AMERICAN MEDICAL DIRECTORS ASSOCIATION, 2016, 17 (01) : 59 - 64
  • [37] Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study
    Shih, Chia-Jen
    Lee, Yi-Jung
    Lo, Yuan-Hao
    Kuo, Shu-Chen
    Ou, Shuo-Ming
    Chen, Yung-Tai
    MAYO CLINIC PROCEEDINGS, 2016, 91 (07) : 867 - 872
  • [38] Dipeptidyl Peptidase-4 Inhibitors and the Risk of Skin Cancer among Patients with Type 2 Diabetes-Population-Based Cohort Study
    Pradhan, Richeek
    Azoulay, Laurent
    Platt, Robert W.
    Yu, Oriana Hoi Yun
    DIABETES, 2023, 72
  • [39] Dipeptidyl peptidase-4 inhibitors and the risk of skin cancer among patients with type 2 diabetes: Population-based cohort study
    Pradhan, Richeek
    Azoulay, Laurent
    Platt, Robert W.
    Yu, Oriana H. Y.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 13 - 13
  • [40] Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study
    Abrahami, Devin
    Douros, Antonios
    Yin, Hui
    Yu, Oriana Hoi Yun
    Renoux, Christel
    Bitton, Alain
    Azoulay, Laurent
    BMJ-BRITISH MEDICAL JOURNAL, 2018, 360
12345